Final NICE rejection for Biomarin’s childhood rare disease drugAfter a year of negotiations NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease Share XFinal NICE rejection for Biomarin’s childhood rare disease drughttps://pharmaphorum.com/news/final-nice-rejection-for-biomarins-childhood-rare-disease-drug/
